Related Experiment Videos
Prostaglandin derivates as ocular hypotensive agents
1Department of Ophthalmology, University Hospital, Uppsala University, Sweden.
Progress in Retinal and Eye Research
|August 8, 1998
Summary
Prostaglandin analogues like latanoprost effectively lower intraocular pressure (IOP) by increasing fluid outflow through the uveoscleral pathway. While generally safe, latanoprost can cause iris pigmentation, unlike unoprostone.
Area of Science:
- Ophthalmology
- Pharmacology
- Glaucoma Research
Background:
- Prostaglandins naturally reduce intraocular pressure (IOP), but PGF2 alpha causes side effects.
- Latanoprost and unoprostone are prostaglandin analogues used clinically for IOP reduction.
Purpose of the Study:
- To evaluate the efficacy and side effects of prostaglandin analogues in lowering IOP.
- To understand the mechanism of action and systemic safety profile of latanoprost.
Main Methods:
- Long-term studies involving once-daily application of 0.005% latanoprost.
- Assessment of IOP reduction, outflow pathways, and systemic concentrations.
- Evaluation of side effects, including iris pigmentation and systemic adverse events.
Main Results:
- Latanoprost effectively reduces IOP, comparable to beta-blockers, via increased uveoscleral outflow.
- Systemic concentrations of latanoprost are low with a short half-life, leading to no observed systemic side effects.
- The most common side effect is iris pigmentation due to melanocyte stimulation; unoprostone has similar efficacy but no reported iris effects.
Conclusions:
- Latanoprost offers a new pharmacological approach for glaucoma treatment by enhancing uveoscleral outflow.
- Latanoprost is safe for systemic use, with iris pigmentation being the primary ocular side effect.
- Unoprostone shares the mechanism of action, with limited data on iris color changes.